Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

John Baker says the founding team opened a £1 profiling shop on King's College campus in 2021. They used it to build the first high-resolution dataset of 1,000 immune systems, now shown on the office wall as the healthy-immune reference. That scrappy sampling gave IMU a population baseline before UK Biobank.

Related Insights

The lack of comparable developability data is a major bottleneck. Natural Antibody's CEO suggests a 'walk before you can run' approach: instead of accounting for all variables, the industry should create a foundational dataset under a single condition. This focused dataset has proven transferable predictive power.

In a UK-wide immuno-oncology program, John Baker says IMU's pre-treatment immune profile separates patients likely to respond to anti-PD-L1 or checkpoint inhibitor combinations. It also flags before the first dose who may suffer severe immune-mediated adverse events, so clinicians can monitor and manage those patients more actively. Response rates are only 30-40%.

A simple, low-cost Complete Blood Count (CBC) test contains a valuable metric for immune health: the lymphocyte-to-monocyte ratio. A low ratio is consistently associated with poorer outcomes across numerous diseases, from cancer to cardiovascular disease, yet this data point is almost universally ignored by clinicians.

John Baker says IMU has about 35 people in Canary Wharf, the vast majority of its global team. He claims the wet-lab and in-silico platform is efficient enough for that team to handle the full Biobank volume, which runs from a few hundred samples now to tens or hundreds of thousands.

Infinimmune’s platform bypasses traditional discovery methods by reading antibodies directly from human memory B cells. The core insight is that the immune system has already spent a lifetime selecting and validating the most effective antibodies, providing a superior, de-risked starting point for new human therapeutics.

The UK Biobank's decision to allow broad access to its genetic data for both commercial and academic researchers resulted in a 100x greater impact than more restrictive biobanks in the US. This success highlights how open data strategies can dramatically accelerate scientific and commercial innovation.

John Baker says live Biobank blood cells are destroyed once a tube is taken out and run on IMU's platform, and many samples are aged. To maximize each one, IMU extracts hundreds of millions of proteomic immunology measurements plus high-resolution single-cell gene expression, then uses neural networks to map those datasets together.

Demonstrating extreme conviction, Noetik invested a year and a half in lab setup, tumor sourcing, and data processing before having a dataset large enough to train its first models. This highlights the immense upfront investment and risk required for a data-first approach in bio-AI, where no off-the-shelf data exists.

John Baker says the immune system shifts with breakfast, exercise and circadian rhythms, yet some anchoring features stay consistent for years or decades. IMU wants to separate those stable anchors from the modifiable parts so it can understand disease progression and treatment effects across a population over time.

Unlike big pharma, capital-constrained biotechs can't afford long, expensive trials. MindImmune’s CEO advocates for designing clever Phase 1b studies that use biomarker endpoints to get an early efficacy signal in months, not years, thereby de-risking the program for investors much faster.

IMU charged £1 to build its first immune baseline | RiffOn